Globus Medical (GMED) Projected to Post Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.79 per share and revenue of $734.5760 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 7th. The medical device company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.10. The company had revenue of $745.34 million during the quarter, compared to the consensus estimate of $738.91 million. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%.The firm’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 earnings per share. On average, analysts expect Globus Medical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Globus Medical Trading Up 1.4%

NYSE GMED opened at $61.21 on Tuesday. The stock has a 50-day simple moving average of $59.36 and a 200 day simple moving average of $59.95. The company has a market capitalization of $8.27 billion, a PE ratio of 23.54, a P/E/G ratio of 1.68 and a beta of 1.12. Globus Medical has a 12 month low of $51.79 and a 12 month high of $94.93.

Insider Buying and Selling at Globus Medical

In other news, Director Ann D. Rhoads sold 10,000 shares of the company’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $58.46, for a total transaction of $584,600.00. Following the completion of the transaction, the director directly owned 25,384 shares of the company’s stock, valued at $1,483,948.64. This represents a 28.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 18.51% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Quantinno Capital Management LP boosted its position in Globus Medical by 79.4% during the second quarter. Quantinno Capital Management LP now owns 13,450 shares of the medical device company’s stock valued at $794,000 after purchasing an additional 5,952 shares during the last quarter. Brevan Howard Capital Management LP acquired a new position in Globus Medical during the second quarter valued at approximately $547,000. NewEdge Advisors LLC boosted its position in Globus Medical by 28.1% during the second quarter. NewEdge Advisors LLC now owns 7,204 shares of the medical device company’s stock valued at $425,000 after purchasing an additional 1,579 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Globus Medical in the second quarter valued at approximately $398,000. Finally, Oxford Asset Management LLP acquired a new stake in shares of Globus Medical in the second quarter valued at approximately $355,000. 95.16% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GMED has been the subject of several recent analyst reports. Stifel Nicolaus initiated coverage on Globus Medical in a report on Tuesday, October 28th. They issued a “hold” rating and a $64.00 price target for the company. Wall Street Zen downgraded Globus Medical from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a report on Monday, July 21st. Morgan Stanley lowered their price target on Globus Medical from $75.00 to $68.00 and set an “overweight” rating for the company in a report on Tuesday, July 15th. Finally, Royal Bank Of Canada set a $88.00 price target on Globus Medical in a report on Friday, October 10th. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, Globus Medical has an average rating of “Moderate Buy” and a consensus target price of $84.55.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.